Oncolytic virus and uses thereof
AssigneeSillajen, Inc.
InventorsKeunhee OH, Namhee LEE, Byung Jin JUNG, Jun Seung LEE, Kyeong Tae KANG
Life of this patent
Estimating the term…
Loading patent…
AssigneeSillajen, Inc.
InventorsKeunhee OH, Namhee LEE, Byung Jin JUNG, Jun Seung LEE, Kyeong Tae KANG
Estimating the term…
The present invention relates to an oncolytic virus and the use thereof, specifically, an oncolytic virus having suppressed thymidine kinase (TK) gene expression and comprising genes encoding granulocyte-macrophage colony-stimulating factor (GM-CSF) and a complement regulatory protein; and the use of such an oncolytic virus. The oncolytic virus of the present invention maintains its efficacy even when administered intravenously, and thus, it may also be applied to the treatment of various solid cancers and metastatic cancers in addition to superficial solid cancers. In addition, the oncolytic virus of the present invention acquires resistance to complement attack by expressing a complement regulatory protein on the surface of the virus, and thus, it is stable in the blood, and it maintains stable oncolytic activity when intravenous injection, and thus, it may reduce effective viral dosage to minimize the side effects of anti-cancer drugs.
An oncolytic virus having suppressed thymidine kinase (TK) gene expression and comprising genes encoding granulocyte-macrophage colony-stimulating factor (GM-CSF) and a complement regulatory protein.
13-15. (canceled)
A genetic construct for insertion into an oncolytic virus, comprising all or part of a gene encoding granulocyte-macrophage colony-stimulating factor (GM-CSF), a gene encoding a transmembrane domain of a vaccinia virus membrane protein and a gene encoding a complement regulatory protein, and operably linked to an early-late promoter and a late promoter for expression.
(canceled)
23-24. (canceled)
Dependencies are inferred from the claim text.